NCT06568042已完成2 期
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 558
- 试验地点
- 143
- 主要终点
- Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)
研究概览
简要总结
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
Participation may last up to 30 weeks including screening.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a Visual Analog Scale (VAS) pain value ≥40 and <95 at screening.
- •Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury, such as metabolic, toxic exposure, nutritional, immunologic, infectious, hereditary, multifactorial, or no known cause identified (idiopathic), of symmetrical nature and in lower extremities (with or without involvement of the hands).
- •Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain- relieving therapies and/or nutritional supplements and will not start any new nonpharmacologic pain-relieving therapies and/or nutritional supplements during study participation.
- •Are willing to discontinue all medications taken for chronic pain conditions, except the allowed pain medications.
- •Individuals NOT of childbearing potential may participate in the trial. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
排除标准
- •Other etiologies of pain that may not be due to DSP or confound the assessment due to painful DSP.
- •Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest.
- •Have not achieved glycemic control on a stable diabetes treatment regimen for at least 90 days prior to screening, have a healthcare provider who manages the participants' diabetes, and have a hemoglobin A1c (HbA1c) >11% at screening.
- •Cancer within 2 years of baseline, except for:
- •cutaneous basal cell or squamous cell carcinoma resolved by excision, or
- •cancer treatment which led to chemotherapy that caused distal sensory polyneuropathy.
- •Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
- •Have a surgery planned during the study for any reason.
- •History of chronic alcohol, illicit drug, or narcotic use disorder within 2 years prior to screening.
研究组 & 干预措施
LY3848575 Dose 3
Experimental
LY3848575 high dose administered SC.
干预措施: LY3848575 (Drug)
Placebo
Placebo Comparator
Placebo administered SC.
干预措施: Placebo (Drug)
LY3848575 Dose 1
Experimental
LY3848575 low dose administered subcutaneously (SC).
干预措施: LY3848575 (Drug)
LY3848575 Dose 2
Experimental
LY3848575 mid dose administered SC.
干预措施: LY3848575 (Drug)
结局指标
主要结局
Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)
时间窗: Baseline, Week 12
次要结局
- Mean Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS)(Baseline, Week 12)
- Mean Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Custom Form (CF) v1.1(Baseline, Week 12)
- Mean Change from Baseline in Pain Interference with Sleep(Baseline, Week 12)
- Mean Change from Baseline in PROMIS Short Form (SF) Physical Functioning (PF) 10a (PROMIS PF 10a)(Baseline, Week 12)
- Mean Change from Baseline in PROMIS (SF) Sleep Disturbance 8b (PROMIS SD 8b)(Baseline, Week 12)
- Mean Change from Baseline in 36-Item Short Form Health Survey Version 2 (SF-36 v2)(Baseline, Week 12)
- Mean Change from Baseline in Patient's Global Impression (PGI) of Illness Severity as Measured by PGI-Severity(Baseline, Week 12)
- Mean Overall Improvement as Measured by Patient's Global Impression of Change(Week 12)
- Use of Rescue Medication(Baseline up to Week 12)
- Pharmacokinetic (PK): Serum Concentration of LY3848575(Baseline up to Week 12)
研究者
研究点 (143)
Loading locations...
相似试验
已完成
2 期
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)SchizophreniaNCT00848484Merck Sharp & Dohme LLC54
已完成
2 期
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaSarcopeniaLiver CirrhosisNCT04874350Lipocine Inc.30
已完成
2 期
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderOpioid Use DisorderNCT06384157Indivior Inc.300
进行中（未招募）
2 期
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDParkinson's DiseaseNCT05819359Bial R&D Investments, S.A.237
终止
2 期
An Efficacy and Safety Study of Palovarotene for the Treatment of MOExostoses, Multiple HereditaryNCT03442985Clementia Pharmaceuticals Inc.193